中国临床药理学杂志2024,Vol.40Issue(21) :3142-3146.DOI:10.13699/j.cnki.1001-6821.2024.21.015

尼美舒利分散片在中国健康受试者中的生物等效性研究

Bioequivalence study of nimesulide dispersible tablets in Chinese healthy subjects

林柏炀 胡荣 张望刚 严静
中国临床药理学杂志2024,Vol.40Issue(21) :3142-3146.DOI:10.13699/j.cnki.1001-6821.2024.21.015

尼美舒利分散片在中国健康受试者中的生物等效性研究

Bioequivalence study of nimesulide dispersible tablets in Chinese healthy subjects

林柏炀 1胡荣 2张望刚 3严静4
扫码查看

作者信息

  • 1. 浙江中医药大学研究生院,浙江 杭州 310053;浙江医院Ⅰ期临床试验研究室,浙江 杭州 310030
  • 2. 南昌市飞弘药业有限公司,江西南昌 330096
  • 3. 浙江医院Ⅰ期临床试验研究室,浙江 杭州 310030
  • 4. 浙江医院重症医学科,浙江 杭州 310030
  • 折叠

摘要

目的 比较尼美舒利分散片(受试制剂)和尼美舒利片(参比制剂)两制剂在中国健康受试者中的药代动力学参数,评价2种制剂的生物等效性.方法 本试验用单中心、随机、开放、两制剂、两周期、双交叉的试验设计,纳入空腹组和餐后组各28例健康受试者,每周期单次口服尼美舒利受试制剂或参比制剂0.1 g,血液采集后,用液相色谱-串联质谱(LC-MS/MS)法测定人血浆中尼美舒利含量,计算药代动力学参数并进行生物等效性评价.结果 在空腹组中,尼美舒利受试制剂和参比制剂主要药代动力学参数:Cmax分别为(6 262.14±1 213.98)和(6 625.36±1 230.09)ng·mL-1,AUC0-t分别为(4.48 × 104±1.66 × 104)和(4.50 ×104±1.53×104)h·ng·mL-1,AUC0-∞ 分别为(4.60 × 104±1.83 × 104)和(4.62 × 104±1.68 ×104)h·ng·mL-1.在餐后组中,尼美舒利受试制剂和参比制剂主要药代动力学参数:Cmax分别为(6 934.29±1 371.00)和(6 551.85±1 383.91)ng·mL-1,AUC0-t分别为(4.43 × 104±1.52 × 104)和(4.50×104±1.47×104)h·ng·mL-1,AUC0-∞ 分别为(4.56 × 104±1.67 × 104)和(4.64 ×104±1.60×104)h·ng·mL-1.在空腹组和餐后组中,受试制剂和参比制剂Cmax、AUC0-t、AUC0-∞的几何均值比值的90%置信区间均落在80.00%~125.00%.空腹和餐后试验的不良事件发生率均为25.00%(7例/28例).结论 受试制剂尼美舒利分散片和参比制剂尼美舒利片在中国健康受试者体内具有生物等效性.

Abstract

Objective To compare the pharmacokinetic parameters of nimesulide dispersible tablets(test preparation)and nimesulide tablets(reference preparation)in Chinese healthy subjects and to evaluate the bioequivalence of two formulations.Methods This trial used a single-centre,randomised,open,two-preparation,two-cycle,two-way crossover experimental design.28 subjects were enrolled under fasting and fed conditions,who received a single oral dose of 0.1 g of nimesulide in the test or reference formulation each cycle.Plasma nimesulide concentration was determined by liquid chromatography-tandem mass spectrometry(LC-MS/MS),calculation of pharmacokinetic parameters and bioequivalence evaluation.Results In fasting group,main pharmacokinetic parameters of the subject and reference formulations of nimesulide:Cmax were(6 262.14±1 213.98)and(6 625.36±1 230.09)ng·mL-1,AUC0-t were(4.48 × 104±1.66 × 104)and(4.50 × 104±1.53 × 104)h·ng·mL-1,AUC0-∞ were(4.60 × 104±1.83 × 104)and(4.62 × 104±1.68 × 104)h·ng·mL-1.In fed group,main pharmacokinetic parameters of the subject and reference formulations of nimesulide:Cmax were(6 934.29±1 371.00)and(6 551.85±1 383.91)ng·mL-1,AUC0-t were(4.43 × 104±1.52 × 104)and(4.50 × 104±1.47 × 104)h·ng·mL-1,AUC0-∞ were(4.56 × 104±1.67 × 104)and(4.64 × 104±1.60 × 104)h·ng·mL-1.The 90%confidence intervals for the geometric means of Cmax,AUC0-t,AUC0-∞ for reference and test preparations in the fasting and fed groups were in the range of 80.00%to 125.00%.The incidence of adverse events in both fasting and fed trials was 25.00%(7 cases/28 cases).Conclusion Nimesulide dispersible tablets were bioequivalent to the reference formulation nimesulide tablets in Chinese healthy subjects when taken under both fasting and fed conditions.

关键词

尼美舒利分散片/生物等效性/安全性评价/液相色谱-串联质谱法

Key words

nimesulide dispersible tablets/bioequivalence/safety evaluation/liquid chromatography-tandem mass spectrometry

引用本文复制引用

出版年

2024
中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCDCSCD北大核心
影响因子:1.91
ISSN:1001-6821
段落导航相关论文